Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
27 recruiting
Showing 1–20 of 78 trials
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled404 locationsNCT05920356
Recruiting
Phase 2
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Acute Lymphoblastic Leukemia, Pediatric
Hyoung Jin Kang74 enrolled10 locationsNCT06257394
Recruiting
Phase 2
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Myotonic Dystrophy 1
PepGen Inc24 enrolled8 locationsNCT06667453
Recruiting
Phase 2
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
Leukemia, Lymphoid
Yonsei University40 enrolled10 locationsNCT06516679
Recruiting
Phase 2
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Pediatric Acute Lymphoblastic Leukemia
Jae Wook Lee370 enrolled9 locationsNCT06184009
Recruiting
Phase 2
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
Lymphoblastic Leukemia in Children
Hee Young Ju116 enrolled13 locationsNCT06099366
Recruiting
Phase 2
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
Acute Lymphoid Leukemia
Ho Joon Im90 enrolled10 locationsNCT05827549
Recruiting
Phase 2Phase 3
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Achondroplasia
BioMarin Pharmaceutical160 enrolled19 locationsNCT07441876
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled351 locationsNCT06875310
Recruiting
Phase 3
A Study of Brenipatide in Participants With Alcohol Use Disorder
Alcohol Use Disorder
Eli Lilly and Company1,100 enrolled117 locationsNCT07219953
Recruiting
Phase 3
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Alcohol Use Disorder
Eli Lilly and Company1,100 enrolled120 locationsNCT07219966
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled419 locationsNCT06119581
Recruiting
Phase 3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb750 enrolled274 locationsNCT07361510
Recruiting
Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled563 locationsNCT07165028
Recruiting
Phase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Eli Lilly and Company1,431 enrolled258 locationsNCT07415044
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled162 locationsNCT07321886
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled366 locationsNCT06890598
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled103 locationsNCT06510374
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled632 locationsNCT06935370